Resmetirom Lowers Cardiovascular Risks in MASH Patients
A recent real-world analysis presented at the American College of Gastroenterology 2026 Annual Scientific Meeting revealed that patients with metabolic dysfunction-associated steatohepatitis (MASH) treated with resmetirom faced a lower risk ... Read More